On the Antigenic Determinants of the Lipopolysaccharides of
Vibrio cholerae O:1, Serotypes Ogawa and Inaba*
Jin
Wang
,
Sylvain
Villeneuve§,
Jian
Zhang
,
Ping-sheng
Lei
,
Charles E.
Miller
,
Pierre
Lafaye¶,
Farida
Nato¶,
Shousun C.
Szu
,
Arthur
Karpas
,
Slavomír
Bystricky
,
John B.
Robbins
,
Pavol
Ková
,
Jean-Michel
Fournier§, and
Cornelis P. J.
Glaudemans
**
From the
Laboratory of Medicinal Chemistry, NIDDK and
the
Laboratory of Developmental and Molecular Immunity, NICHD,
National Institutes of Health, Bethesda, Maryland 20892 and the
§ Unité du Choléra et des Vibrions, Centre
National de Référence des Vibrions et du Choléra and
¶ Hybridolab, Institut Pasteur, 75724 Paris Cedex 15, France
 |
ABSTRACT |
Monoclonal, murine IgG1s
S-20-4, A-20-6, and IgA 2D6, directed against Vibrio
cholerae O:1 Ogawa-lipopolysaccharide exhibited the same fine
specificities and similar affinities for the synthetic methyl
-glycosides of the (oligo)saccharide fragments mimicking the Ogawa
O-polysaccharide (O-PS). They did not react with the corresponding
synthetic fragments of Inaba O-PS. IgG1s S-20-4 and A-20-6
have absolute affinity constants for synthetic Ogawa mono- to
hexasaccharides of from ~105 to ~106
M
1. For IgG1s S-20-4, A-20-6, and
IgA 2D6, the nonreducing terminal residue of Ogawa O-PS is the dominant
determinant, accounting for ~90% of the maximal binding energy shown
by these antibodies. Binding studies of derivatives of the Ogawa
monosaccharide and IgGs S-20-4 and A-20-6 revealed that the C-2
O-methyl group fits into a somewhat flexible antibody
cavity and that hydrogen bonds involving the oxygen and, respectively,
the OH at the 2- and 3-position of the sugar moiety as well as the
2
-position in the amide side chain are required.
Monoclonal IgA ZAC-3 and IgG3 I-24-2 are specific for
V. cholerae O:1 serotypes
Ogawa/Inaba-LPS.1 The former
did not show binding with members of either series of the synthetic
ligands related to the O-antigens of the Ogawa or Inaba serotypes, in
agreement with its reported specificity for the lipid/core region (1).
Inhibition studies revealed that the binding of purified
IgG3 I-24-2 to Ogawa-LPS might be mediated by a region in
the junction of the OPS to the lipid-core region of the LPS.
cDNA cloning and analysis of the anti-Ogawa antibodies S-20-4,
A-20-6, and 2D6 revealed a very high degree of homology among the heavy
chains. Among the light chains, no such homology between S-20-4 and
A-20-6 on the one hand, and 2D6 on the other hand, exists. For the
anti-Inaba/Ogawa antibodies I-24-2 and ZAC-3, their heavy chains are
completely different, with some homology among the light chains.
 |
INTRODUCTION |
Vibrio cholerae O:1 is subdivided into two serological
types, Inaba and Ogawa. The internal part of their O-polysaccharide chains (O-antigen) are homopolymers of (1
2)-linked linear
4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-
-D-mannopyranosyl residues. The two types apparently differ by the presence of a 2-O-methyl group in the nonreducing terminal sugar of the
Ogawa O-antigen, absent in the Inaba O-antigen (2, 3).
We used synthetic mono- to hexasaccharides that mimic the fragments of
the O-antigen of Ogawa and Inaba O-polysaccharides (2-4), together
with certain analogs of their monosaccharides to evaluate specificity.
The binding of three immunoglobulins G (two specific for Ogawa
and one specific for Ogawa/Inaba) and of two immunoglobulins A (one
specific for Ogawa and one specific for Inaba/Ogawa) were characterized
by ligand-induced fluorescence titration or ELISA inhibition. The
cDNA sequences of these antibodies are also presented in this
report.
 |
MATERIALS AND METHODS |
Monoclonal Antibodies--
Murine ascites fluids of A-20-6 and
S-20-4 both contain vibriocidal IgG1 specific for
Ogawa-LPS. I-24-2, in contrast, contains IgG3 specific for
both serotypes Ogawa and Inaba-LPS, and it has low vibriocidal activity
(5) (clone S-20-4 comes from the same hybridoma cells as clone S-20-3
described in this reference). Murine ascites fluid 2D6 and ZAC-3
contain IgA specific for Ogawa-LPS and IgA specific for
Inaba/Ogawa-LPS, respectively. The latter two hybridomas were gifts
from Drs. Marian Neutra, Harvard Medical School, and Dr. Richard
Weltzin, Oravax, Cambridge, MA (1, 6) and were grown in BALB/c mice.
IgGs were purified using ImmunoPure® (G) IgG purification kits
(Pierce). Briefly, ascites fluid (2 ml, clarified by centrifugation)
was mixed with ImmunoPure® (G) binding buffer (2 ml) and applied to a
protein G column. After washing the column with 5 × 2-ml aliquots
of the ImmunoPure® (G) binding buffer, the bound IgG was eluted with 6 ml of ImmunoPure® (G) elution buffer, dialyzed against PBS, pH 7.4 (2000 ml) for three changes at 0 °C, frozen, and labeled. The
purified A-20-6, S-20-4, and I-24-2 showed a single arc of
precipitation versus goat anti-mouse IgG1 and
IgG3, respectively (heavy chain-specific), and goat
anti-whole mouse serum (Sigma) by immunoelectrophoresis. IgAs were
purified from ascites fluid by 40% ammonium sulfate precipitation and
anion-exchange DEAE-Sephadex A-25 chromatography (7). Monomeric IgA was
obtained by mild reduction with 5 mM 1,4-dithiothreitol
(Sigma) and alkylation with 11 mM 2-iodoacetamide (Sigma),
followed by re-adsorption of the sample on DEAE-Sephadex A-25 and
elution with PBS, pH 7.4. The purity of IgAs was also verified by
immuno-electrophoresis against anti-mouse IgA and serum and
SDS-polyacrylamide gel electrophoresis.
LPS and Synthetic Oligosaccharides--
V. cholerae
O:1 LPSs were obtained from acetone-treated cells of strain 569B,
classical biotype, serotype Inaba, lot VC1219; strain 3083, classical
biotype, serotype Ogawa; and V. cholerae O:139 Bengal,
strain 4450. Salmonella paratyphi A LPS was a field isolate
in Nepal, strain NTP-6. All LPSs were purified as described (8) and at
2 mg/ml showed negative tests (Coomassie Blue) for protein. Severely
base-degraded V. cholerae O:139 LPS (9) was a gift from Dr.
Andrew D. Cox, National Research Council, Ottawa, Canada.
De-O-acylated Ogawa-LPS (10) was oxidized in aqueous 0.8%
periodate solution for 3 days in the dark, dialyzed, and freeze-dried
and then reduced in aquous sodium borohydride (11) to convert aldehyde
groups to alcohol groups to give O/R-DeOAc-Ogawa-LPS. Assays, as
glucose (12), for carbonyl groups in both the oxidized and oxidized and
reduced samples showed the reduction to be 99.1% complete. The
synthesis of methyl
-isomaltoside has been described (13).
D-Glucose, methyl
-D-glucopyranoside, methyl
-D-glucopyranoside, D-galactose, methyl
-D-galactopyranoside, D-mannose, methyl
-D-mannopyranoside, D-mannoheptose,
D-glucosamine hydrochloride,
2-keto-3-deoxy-D-manno-octonate, D-fructose,
and dextran 10T were purchased from Sigma. Methyl
-D-fructofuranoside was obtained from the National
Institutes of Health Carbohydrate Collection. Synthetic methyl
-glycosides of the mono- to hexasaccharides of the O-antigen of
V. cholerae O:1, serotypes Ogawa (1O
to 6O) (Fig. 1)
and Inaba (1I to 6I), as
well as the preparation of methyl
4-acetamido-4,6-dideoxy-2-O-methyl-
-D-mannopyranoside (1O-Ac), methyl
4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-2-O-ethyl-
-D-mannopyranoside (1O-Et), methyl
4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-2-O-n-propyl-
-D-mannopyranoside (1O-Pr) methyl
2,4,6-trideoxy-4-(3-deoxy-L-glycero-tetronamido)-
-D-mannopyranoside (1-2d), methyl
3,4,6-trideoxy-4-(3-deoxy-L-glycero-tetronamido)-
-D-mannopyranoside (1O-3d), methyl
4,6-dideoxy-4-(3-deoxy-D-glycero-tetronamido)-2-O-methyl-
-D-mannopyranoside(1O-D),
methyl
4,6-dideoxy-4-(4-hydroxybutyramido)-2-O-methyl-
-D-mannopyranoside (1O-2
d), methyl
4,6-dideoxy-4-(3,4-dideoxy-L-glycero-tetronamido)-2-O-methyl-
-D-mannopyranoside (1O-4
d), and methyl
4,6-dideoxy-4-(2-deoxy-L-glycero-tetronamido)-2-O-methyl-
-D-mannopyranoside (1O-2
d,3
OH) have been described
elsewhere (14-20).
3-Deoxy-N-isopropylidene-L-glycero-tetronic acid hydrazide (TAH) was prepared as follows:
3-deoxy-L-glycero-tetronic acid hydrazide and
3-deoxy-N-isopropylidene-L-glycero-tetronic acid hydrazide (TAH): a mixture of
3-deoxy-L-glycero-tetronolactone (16) (1 g) and
hydrazine hydrate (17 ml) was stirred at room temperature overnight,
when TLC (5:1 CH2Cl2-MeOH) showed that all
starting lactone was consumed. The solution was concentrated to give a
solid residue (1.4 g, ~100%). Crystallization from MeOH-EtOAc gave
3-deoxy-L-glycero-tetronic acid hydrazide, m.p.
108-108.5 °C, [
]D
18.8° (c 0.8, H2O). 1H NMR (D2O):
4.28 (dd, 1 H, J2,3a 4.0, J2,3b 8.8 Hz, H-2), 3.70 (deceptively simple dd, 2 H, J 5.7 and 7.3 Hz, 2J not observed, H-4a, b), 2.06-1.95,
1.87-1.76 (2 m, 2 H, H-3a, b); 13C NMR
(CDCl3):
174.97 (CO), 68.34 (C-2), 57.81 (C-4), 35.92 (C-3); chemical ionization mass spectroscopy: m/z 135 ([M + 1]+), 152 ([M + 18]+).
|
|
|
|
A solution of 3-deoxy-L-glycero-tetronic
acid hydrazide (1 g) was treated with 1:2 MeOH-acetone (6 ml) at
50 °C for 15 min. Crystaline, pure (TLC, NMR)
N-isopropylidene derivative TAH, was obtained
upon concentration to a small volume, m.p. 116~117° and
[
]D
18.5° (c 1, H2O).
1H NMR (CD3OD):
4.26 (dd, 1 H,
J2,3a 3.9, J2,3b 8.6 Hz,
H-2), 3.69 (deceptively simple t, 2 H, J 6.6 Hz, H-4a, b),
2.12, 1.92 (2 s, overlapped, 2 CH3), 2.12-1.90 (m,
overlapped, H-3a), 1.87-1.70 (m, 1 H, H-3b); chemical ionization mass
spectroscopy: m/z 175 ([M + 1]+), 192 ([M + 18]+).
|
|
|
|
All saccharides were dried at 40 °C in vacuum (1 torr)
overnight and then dissolved in distilled water.
cDNA Synthesis, Amplification Cloning, and
Sequencing--
Hybridomas for the monoclonal antibodies 2D6 and ZAC3,
provided by Oravax, were used to prepare cDNA: poly(A)+
RNA from approximately 1.5 × 107 cells was purified
by the guanadine isothiocyanate method (Quikprep Micro, Pharmacia
Biotech Inc.). Synthesis of the cDNA strand was accomplished by
extension of approximately 1 µg of poly(A)+ mRNA with
primers specific for Ig C
(5
-TAC ATT GGA TCC TTA AGG
AGG AGG AGG AGT AGG-3
) and Ig C
(5
-AGG CTT AAG CTT TTA ACA CTC ATT
CCT GTT GAA-3
). Reaction conditions for the synthesis of the first
strand were as recommended (Superscript first strand synthesis, Life
Technologies, Inc.). Following synthesis of the cDNA by reverse
transcriptase, polymerase chain reaction (PCR) was achieved with
primers for the constant region used in the extension reaction in
combination with one of a series of hybridizing V region primers.
Positive PCR products were obtained with the VH primer
(5
-GCA AGC TTG TCG ACG TGC AGC T(GT)(CA) AG(CG) AGT C(AG)GG-3
for
ZAC3, 5
-GCA AGC TTG TCG ACG TGA AGC T(TG)(GC) (AT)(CG)GA (AG)TC TGG-3
for 2D6) and the VL primer (5
-AGG CTT GAA TTC ATG TTG TGA
TGA CCC A-3
for both 2D6 and ZAC3). Thirty cycles of amplification
were applied using 20 pmol of each flanking primer in a reaction
mixture containing the Elongase enzyme mix (Life Technologies, Inc.) at
a concentration of 1.5 mM KCl. Thirty cycles of
denaturation (94 °C), annealing (55 °C), and extension (72 °C)
were done in a DNA thermal cycler (Ericomp).
Positive PCR products were purified on 1.0% low melting agarose gels
using AgarACE enzyme (Promega) to extract the DNA and ligated to pCRII
vectors as described by the manufacturer (Invitrogen). White colonies
were selected and screened by restriction analysis for cloned inserts.
The isolated VL and VH clones were grown in YT
medium to produce phage, and the single-stranded DNA was purified (21).
The DNA was then subjected to single-stranded DNA sequencing according
to the protocol provided by the manufacturer (Sequenase, U. S.
Biochemical Corp.).
For the hybridoma cells producing A-20-6, S-20-4, and I-24-2
antibodies, the total RNA was extracted by a modification of a known
method (22). The reaction mixture (100 µl) containing maximally 10 µg of total RNA, 20 mM mercaptoethanol, 80 units of
RNasin (RNase inhibitor, Promega) 1 × first strand buffer (Life Technologies, Inc., Basel, Switzerland), 8 mM
dithiothreitol, 0.1 µg/ml primer p(dT)15 (Boehringer
Mannheim GmbH, Mannheim, Germany), 500 µM each dNTP, and
400 units of Moloney murine leukemia virus reverse transcriptase
(Promega, using their protocols) was incubated for 2 h at
42 °C. The reaction mixture was then used directly for PCR
amplification. For that, each cDNA mixture so obtained was divided
into, respectively, eight (for the VH) and ten (for the VL) separate
mixtures, each one of which was then treated with the appropriate,
separate, back primers. A 50-µl reaction mixture containing 2 µl of
the reaction mixture from the cDNA synthesis, 30 pmol of one of the
back primers, 30 pmol of forward primer, 500 µM dNTP, 1 mmol of MgSO4, 0.05 × Thermopol buffer, and 1 unit of
Vent DNA polymerase (New England Biolabs) or Taq DNA
polymerase (U. S. Biochemical Corp.). The reaction mixture was
subjected to 40 cycles of amplification, each one 1-min denaturation,
1-min annealing (54 °C), and 2-min extension (72 °C). Products (5 µl) were analyzed on a 2% agarose gel.
The back primer that yielded products used in the amplification of the
VH of clones A-20-6 and S-20-4 was VH3-D
(5
-GAA GTT AAG CTC GAG CAG TCT GGA GC-3
), and the
-chain primer
(CH) used as forward primer was
1 (5
-AGG CTT ACT AGT
ACA ATC CCT GGG CAC AAT-3
) for the clones A-20-6 and S-20-4. For the
VH of I-24-2 the Pharmacia heavy chain primer kit was used
to amplify the VH. The primers used for the amplification
of each VL of three clones were the following: for I-24-2
the back primer VL5 (5
-CCA GAT GTG AGC TCG TGA TGA CCC AGA
CTC CA-3
) was used, while VL10 (5
-GGG AAT TCA TGG CCT GGA
(C,T)T(C,T) C(A,T)CT(T,C)(A,T) T(A,C)(C,T) TCT-3
) was used as the back
primer for A-20-6 and S-20-4. The
-chain primer (CL)
(5
-CCC AAG CTT AGC TC(C,T) TC(A,T) G(A,T)G GA(G,C) GG(C,T) GG(A,G)
AA-3
) was used as forward primer for the clones A-20-6 and
S-20-4. The
-chain primer used for the clone I-24-2 was 5
-GCG CCG
TCT AGA ATT AAC ACT CAT TCC TGT TGA A-3
(23, 24).
The back primers were designed to hybridize to the partially conserved
sequences in the leader or the FR1 regions of the VH or
VL. The forward primers corresponded to the N-terminal
beginning of the hinge region and the C-terminal part of the
CL region, respectively.
Direct sequencing of these PCR products was performed on an Applied
Biosystem Apparatus ABI 373A (Genome Express, Grenoble, France) using
dye terminators. Sequence data were analyzed and comparisons performed,
with software from the Genetics Computer Groups, Inc. (Madison, WI) and
the GeneBankTM (Los Alamos, NM) and EBI (Heidelberg, Germany)
Fluorescence Titration--
Purified immunoglobulins were
diluted with PBS, pH 7.4, to solutions having an
A280 of 0.04. Protein solutions (1.1 ml) were added to each of two cuvettes, one for ligand addition, the other a
reference. A third cuvette filled with 1.1 ml of PBS was used as a
blank. Temperature was maintained at 25 °C by a circulating thermostatic bath. Ligand solutions were verified to show no
fluorescence effects by themselves by addition to a suitable nonbinding
protein. To obtain a good distribution of points, ligand concentrations were adjusted so that the protein would be saturated after the addition
of ~20 µl of ligand solution to the test cell. Affinity constants
(Ka) for the association between ligands and antibodies were obtained by monitoring the ligand-induced tryptophanyl fluorescence of the antibody as a function of ligand concentration (25,
26). We used a Perkin-Elmer LS 50 luminescence spectrophotometer and
|
(Eq. 1)
|
where Ka is the affinity constant,
is the
fraction of antibody sites bound to ligand (measured as the change in antibody fluorescence due to ligand addition, divided by the maximal ligand-induced fluorescence change), 1
is the fraction of free antibody sites, and CL is the concentration of free
ligand. A Scatchard plot of
/CL versus
gives a line whose slope is equal to the Ka. Two
representative Scatchard plots are shown in Fig.
2: one for the Ka of
IgG1 A-20-6 with the Ogawa monosaccharide determinant
1O and one for the Ka of
IgG1 S-20-4 with the Ogawa pentasaccharide
5O. These are expressed either in
M
1 or (Table I) as the free energy (kJ) of
binding (
G0 =
RTlnKa).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Scatchard plots of the Ka
for synthetic mono- and pentasaccharides mimicking the Ogawa O-antigen
fragment with immunoglobulins G1 A-20-6 and S-20-4,
respectively.
|
|
ELISA for Inhibition of Antibody Binding--
The binding
constants for the antibodies that did not show a significant change in
fluorescence following addition of ligand were determined by ELISA
inhibition. For anti-Ogawa IgA 2D6 (6), Ogawa-LPS was the capturing
reagent. In the case of anti Inaba-Ogawa IgA ZAC-3 and IgG3 I-24-2,
both the Ogawa- and Inaba-LPS were used as capturing reagents in
screening with 1O to
4O/1I to
4I, and 1O to
6O/1I to
6I, respectively. In screening of IgG3 I-24-2
with core-related haptens (see Table II), Ogawa-LPS was the capturing
reagent.
For IgA 2D6/Ogawa-LPS, the amount of ligand required for 50%
inhibition in the ELISA was determined. Since Ka =
/(1
) CL (see "Fluorescence Titration"
section), at 50% inhibition, assuming solution behavior in ELISA, we
have that
= (1
). Thus, the reciprocal of the molar
concentration causing 50% inhibition was taken to be the (relative)
Ka. Microtiter plates (96-well; Maxisorb, Nunc,
Denmark) were coated with 100 µl of either Ogawa- or Inaba-LPS (10 µg/ml) in 10 mM MgCl2 PBS solution at room
temperature overnight. Ascites fluids (1:4000 dilution), purified 2D6,
ZAC-3 (1:200 dilution), and purified I-24-2 (1:800 dilution) were
incubated in quadruplicate with inhibitors in various concentrations
(1-2500 µg/ml PBS) or with PBS for 1 h at 37 °C, followed by
4 °C overnight. Samples were centrifuged and supernatants (100 µl)
delivered to microtiter plates. ELISA was performed as described (27).
A standard curve for A405 versus
antibody concentration added without inhibitor was fitted to the
quadratic equation aX2 + bX + c, where X is the optical density observed.
Correlation factors (
) of 0.999 were routinely obtained. Based on
that standard curve, residual, bound antibody in the presence of
inhibitor was determined (AI), and percent inhibition was
calculated as follows: (1
AI) × 100 = % inhibition.
 |
RESULTS AND DISCUSSION |
Antigenic Epitopes on Ogawa-LPS--
IgG1s, A-20-6 and
S-20-4, specific for Ogawa-LPS (vibriocidal titer: 1280), protect mice
from mortal challenge with three times the LD50 of V. cholerae O:1 serotype Ogawa strain 920139 (5). Thus, a study of
their combining sites is of interest, as oligosaccharide fragments of
the O-antigen that bind immunoglobulins maximally will be more likely,
when linked to a carrier protein, to elicit antibodies reactive with
the parent polysaccharides (28). Each synthetic mono- to hexasaccharide
fragment of the Ogawa O-antigen bound the two antibodies, with binding
constants of from ~105 to ~106
M
1 as measured by fluorescence titration
(Table I). The free energies of
association for oligosaccharide with each of the two antibodies were
close, indicating that these two vibriocidal antibodies have the same
fine specificity for the epitope on the Ogawa O-PS. The terminal,
nonreducing Ogawa-monosaccharide (1O)
contributed ~90% of the maximal binding energy shown by the entire
hexasaccharide. This finding differs from those in some other
(homo)polysaccharide-antibody systems (29), where monosaccharide
binding accounts for only 50-60% of the maximum binding energy that
is shown by the binding of four to six sugars. Methyl
4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-2-O-ethyl-
-D-mannopyranoside (1O-Et) showed an affinity constant for
both these antibodies that was an order of magnitude less than that of
the Ogawa monosaccharide. Neither the corresponding monosaccharide with
a free OH group at C-2 (1I), nor its 2-deoxy
derivative (1-2d), 3-deoxy derivative (1O-3d), 2-O-propyl derivative
(1O-Pr), or the one deoxygenated at the
2
-position in the tetronic acid moiety
(1O-2
d), exhibited binding. Removal of the
primary hydroxyl group in the tetronic acid group gave
(1O-4
d), which bound to IgGs A-20-6 and S-20-4
with higher affinity than did 1O itself (Table
I). A hydrophobic pocket of defined size in the antibody might interact
with the 2-O-methyl group of the terminus of the Ogawa O-PS.
Alternatively, the presence of an O-methyl group at C-2
could dictate a particular conformation due to a pattern of hydrogen
bonding that is absent when C-2 bears an OH group. Similarly, increased
hydrophobicity, or differently routed, multiple hydrogen bond
interactions might also explain why 1O-4
d could
have a higher affinity than does 1O. Neither
N-isopropylidene-L-tetronic acid hydrazide
(TAH) nor methyl
4-acetamido-4,6-dideoxy-2-O-methyl-
-D-mannopyranoside (1O-Ac) showed measurable binding. The
monosaccharide corresponding to 1O, but bearing
a D-tetronic group instead of the natural
L-isomer (1O-D), bound to both IgGs
A-20-6 and S-20-4, albeit with an affinity 2 orders of magnitude less
(Ka = ~103
M
1) than did 1O. None
of the synthesized O-antigen saccharidic fragments of the Inaba series,
from mono- to hexasaccharide, i.e. those that lack the
2-O-methyl group in the upstream terminal monosaccharide, bound to either of the two IgGs specific for the Ogawa-LPS. Therefore, the 2-O-methylated, terminal monosaccharide seems to be the
dominant serotype-specific determinant for Ogawa strains. Furthermore, the Ogawa-specific antibodies do not show any appreciable affinity for
internal residues, shared by the O-polysaccharides of both Inaba and
Ogawa strains.
View this table:
[in this window]
[in a new window]
|
Table I
The binding constants (Ka, M 1) and free
energy of association ( G0, kJ/mol) for vibriocidal
immunoglobulins G specific for LPS of serotype Ogawa, V. cholerae O1 with synthetic Ogawa fragments and monosaccharide
derivatives
|
|
Are the fine specificities of the IgA 2D6 (6) and IgGs A-20-6 and
S-20-4 for the same epitope? Since IgA 2D6 did not show ligand induced
fluorescence change, this was investigated by ELISA inhibition of
binding of the IgA to Ogawa-LPS. In Fig.
3 it can be seen that LPS (molecular
weight ~8000 daltons), as well as 1O to
4O inhibit the binding of IgA 2D6 to Ogawa-LPS,
while 1I and1I-2d show
(weak) nonspecific inhibition. The inhibition curves of the Ogawa
tetra- and trisaccharide are identical. There was little difference in
slope between the mono-, di-, tri-, and tetrasaccharide. For 50%
inhibition of the binding of the antibody to Ogawa-LPS, mono-, di-,
tri-, and tetrasaccharides were required in concentrations of 34, 12.5, 5, and 5 µM, respectively. Their relative affinities were
therefore 3 × 104, 8 × 104, 2 × 105, and 2 × 105
M
1, respectively. So, this antibody also
shows a (relative) free energy of binding for the monosaccharide
1O that is quite dominant (some 85% of the free
energy of binding shown by the tetrasaccharide
4O). Thus, our results for the binding of two
vibriocidal IgGs A-20-6 and S-20-4 as well as IgA 2D6 to a series of
saccharides mimicking the Ogawa O-antigen have provided strong evidence
that these anti-Ogawa-LPS IgGs and the IgA are specific for the same antigenic epitope. The terminal monosaccharide, bearing the
2-O-methyl group, in the O-antigen of Ogawa-LPS is most
likely the serotype-specific determinant for the Ogawa strain. It is
not unusual that small determinants can dictate an immune response in
mice (30).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibition curves of the binding of Ogawa-LPS
to sIgA 2D6 using Ogawa-LPS, synthetic mono- to tetrasaccharides
mimicking the fragment of Ogawa O-antigen and Ogawa monosaccharide
derivatives.
|
|
Antigenic Epitopes on Inaba-LPS--
Synthetic oligosaccharide
fragments reflecting the structural difference between Ogawa and Inaba
O-antigens were used to study the specificity of monoclonal IgA ZAC-3,
obtained from a lymphocyte of the mouse's Peyer's patches following
immunization with V. cholerae O:1 serotype Inaba (1), and
monoclonal IgG3 I-24-2, obtained following immunization of
mice with a lysate from V. cholerae O:1 serotype Inaba (5).
Others showed (1) that the IgA ZAC-3 dimer and polymer bound all the
fragments (including the 3-4-kDa fragment) of V. cholerae
LPS (Inaba), indicating that the determinant epitope for this IgA is
located in the lipid A or core region, and not in the O-specific side
chain. These workers also showed by microcalorimetric measurements that
the Ka for IgA ZAC-3 and detergent-solubilized LPS
was ~6 × 105 M
1. Their
proposed specificity of ZAC-3 for the lipid/core (1) would accommodate
our results described below, namely that none of our Ogawa or Inaba
(oligo)saccharides show binding to that IgA.
IgG3 I-24-2 is reported to possess weak agglutination
titers against Ogawa and Inaba organisms and a weak vibriocidal titer against either organism (5). No ligand-induced fluorescence change was
observed with antibody IgG3 I-24-2 and either
1O to 6O or
1I to 6I or with IgA
ZAC-3 and either 1O to 4O
or 1I to 4I. The absence
of binding of these ligands to these two (ZAC-3 and I-24-2) purified
antibodies was verified by ELISA inhibition systems (antibody/Ogawa- or
Inaba-LPS). Indeed, these saccharides also failed to show interaction
with either antibody in the ELISA system employing either LPS-Ogawa or
LPS-Inaba as the capturing agent, except for Inaba monosaccharide
1I, which could moderately inhibit (50%) only
the IgG3 I-24-2/Ogawa-LPS system (see Table
II), but not the ZAC-3/Inaba-LPS or
ZAC-3/Ogawa-LPS ELISA system. (It is puzzling to us why only the mono-
and not the higher oligosaccharides of the Inaba series is able to
inhibit the IgG3 I-24-2/Ogawa-LPS system.) The binding of
either IgA ZAC-3 or I-24-2 to ELISA plates, using either the LPS-Ogawa
or LPS-Inaba as the capturing agent, could be inhibited by either
LPS.
View this table:
[in this window]
[in a new window]
|
Table II
ELISA inhibition study using various inhibitors to inhibit the
binding of the immunoglobulin G3, I-24-2 specific for Ogawa and
Inaba LPSs, to Ogawa-LPS
|
|
To elucidate the inhibitory effect by various other potential
inhibitors in the I-24-2/Ogawa-LPS ELISA system we examined the ligands
shown in Table II. Using whole ascites fluid, Inaba- and Ogawa-LPS were
the most effective inhibitors (90% inhibition). V. cholerae
O:139 LPS, D-glucose, Inaba monosaccharide, and
D-galactose all showed moderate inhibition. The V. cholerae O:139 LPS has a very short O-PS that is structurally
unrelated to the O-PS of V. cholerae O:1 (31-35) and has
its core region in common with that of V. cholerae O:1 Ogawa
and Inaba (9), save for the fact that the O:139 has a branch of
isomaltose instead of just glucose attached to its core. The O:139 LPS
did weakly inhibit the interaction of both ascites fluid and purified
IgG3 I-24-2 with Ogawa-LPS as the capturing reagent.
Severely base-degraded O:139 LPS (9) consists of the core region that
is flanked at the upstream end by the base-stable remnant of its short
O-PS, namely two carbohydrate residues: a
threo-hex-4-enuronopyranosyl residue linked to
2-amino-2,6-dideoxy glucosyl residue, while at the downstream end of
the core two phosphorylated glucosaminyl residues remain. That product
did not react with ascites fluid, but did weakly inhibit the
interaction of purified IgG3 I-24-2 with Ogawa-LPS as the
capturing reagent. O/R-DeOAc-Ogawa-LPS is a substance that has only its
core destroyed by the periodate oxidation (borohydride reduction was
executed to render the aldehydo groups formed chemically unreactive),
since the core has vicinal hydroxyl groups (33). Its O-PS is unaffected by the periodate oxidation, as we showed by measuring its
Ka values with IgGs A-20-6 and S-20-4
(Ka values of 0.5 × 106 and
1.3 × 106, respectively), showing them to be nearly
the same as the Ka values these antibodies have with
the hexameric O-PS saccharide 6O. This
O/R-DeOAc-Ogawa-LPS was able to inhibit IgG3 I-24-2 on
ELISA (see Table II) only 70%, whereas the LPS itself could do so
nearly completely (90%). Since it is unlikely that the lipid plays a
role, this could indicate a partial specificity of IgG3 I-24-2 for the core, as that is the only part of the molecule that
would be destroyed by periodate oxidation. Dextran 10T,
D-glucose, methyl
-glucopyranoside, methyl
-D-glucopyranoside, D-mannose, and methyl
-D-mannopyranoside (the latter two are structurally related to the heptose in the core region) showed moderate to significant (50 or 70%) inhibition. The inhibition by
D-galactose and methyl
-galactopyranoside also remains
unexplained. Although from the above it does appear to recognize
determinants in the core region of the LPS, an immunoblotting
experiment (5), shows IgG3 I-24-2 to bind only to the high
molecular weight LPS from both Inaba and Ogawa V. cholerae
O:1, and not to the low molecular weight fractions, presumably made up
of lipid-core region only (34).
In summary, for the immunoglobulins with specificity for Ogawa/Inaba,
the behavior of the IgG3 I-24-2 indicates partial
specificity for the core as well as for a single residue of
4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-
-D-mannopyranoside. Such a residue is linked, as the first of many in the O-PS, to the core in the Inaba-LPS. Nevertheless the behavior of
IgG3 I-24-2 remains somewhat puzzling. Our observations on
IgA ZAC3 are entirely consistent with the specificity proposed by
Lüllau et al. (1) for the LPS' lipid/core region. For
the binding behavior of the three anti-Ogawa monoclonal antibodies,
IgG1 S-20-4, IgG1 A-20-6, and IgA 2D6, our data
consistently indicate the immunodeterminant to be the upstream,
terminal residue of the Ogawa O-PS.
The above results were corroborated by the cDNA-derived amino acid
sequences. It is clear from the VH sequences of the
anti-Ogawa immunoglobulins (Fig. 4) that
all three belong to the same family, as they show a high degree of
homology. It is interesting that IgGs A-20-6 and S-20-4 have identical
(
) VL regions, whereas IgA 2D6, possessing a
L-chain, has a VL sequence that is therefore quite
different. Since they show identical specificity patterns, that may be
dictated more by the H- than by the L-chain. It is noteworthy that the
IgGs A-20-6 and S-20-4 show significant ligand-induced tryptophanyl
fluorescence change, while IgA 2D6 does not. The former two (IgGs) both
possess a tryptophanyl residue at position L-91, while the latter (IgA)
carries a glycine at that position. Tryptophan at that position of the
L-chain has been correlated before with ligand-induced changes in the
tryptophanyl fluorescence (29).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
The cDNA-derived amino acid sequences of
the anti- Ogawa immunoglobulins IgG1s( ) A-20-6 and
S-20-4, as well as IgA( ) 2D6.
|
|
In comparing the cDNA sequences of IgA ZAC-3 and IgG3
I-24-2 (Fig. 5), we observe the reverse.
Here, the VH sequences differ extensively, while the
VL regions show some degree of homology. It should be
noted, however, that there, most of the differences occur in the
hypervariable regions of the VL.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
The cDNA-derived amino acid sequences of
the anti-Inaba/Ogawa immunoglobulins IgA ZAC-3 and IgG3
I-24-2.
|
|
 |
ACKNOWLEDGEMENT |
We are grateful to Dr. Andrew D. Cox for a
generous gift of severely base degraded V. cholerae O:139
LPS.
 |
FOOTNOTES |
*
This work was supported in part Grant ACC-SV6 (to J.-M.
F.) from the Ministère Français de la Recherche.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed. Tel.: 301-496-1266;
Fax: 301-402-0589; E-mail: glau{at}helix.nih.gov.
1
The abbreviations used are: LPS,
lipopolysaccharide(s); O-PS, O-polysaccharide; ELISA, enzyme-linked
immunosorbent assay; PBS, phosphate-buffered saline; PCR, polymerase
chain reaction.
 |
REFERENCES |
-
Lüllau, E.,
Heyse, S.,
Vogel, H.,
Marison, I.,
von Stockar, U. V.,
Kraehenbuhl, J.-P.,
Corthesy, B.
(1996)
J. Biol. Chem.
271,
16300-16309[Abstract/Free Full Text]
-
Hisatsune, K.,
Kondo, S.,
Isshiki, Y.,
Iguchi, T.,
and Haishima, Y.
(1993)
Biochem. Biophys. Res. Commun.
190,
302-307[CrossRef][Medline]
[Order article via Infotrieve]
-
Ito, T.,
Higuchi, T.,
Hirobe, M.,
Hiramatsu, K.,
and Yokota, T.
(1994)
Carbohydr. Res.
256,
113-128[CrossRef][Medline]
[Order article via Infotrieve]
-
Kenne, L.,
Lindberg, B.,
Unger, P.,
Gustafsson, B.,
and Holme, T.
(1982)
Carbohydr. Res.
100,
341-349[CrossRef][Medline]
[Order article via Infotrieve]
-
Bougoudogo, F.,
Vely, F.,
Nato, F.,
Boutonnier, A.,
Gounon, P.,
Mazie, J.-C.,
and Fournier, J.-M.
(1995)
Bull. Inst. Pasteur
93,
273-283 [CrossRef]
-
Winner, L.,
Mack, J.,
Weltzin, R.,
Mekalanos, J.,
Kraehenbuhl, J.-P.,
and Neutra, M. P.
(1991)
Infect. Immun.
59,
977-982[Medline]
[Order article via Infotrieve]
-
Das, M. K.,
and Glaudemans, C. P. J.
(1978)
Carbohydr. Res.
62,
165-168[CrossRef][Medline]
[Order article via Infotrieve]
-
Westphal, O.,
and Jann, K.
(1965)
Methods Carbohydr. Chem.
5,
83-91
-
Cox, A. D.,
Brisson, J.-R.,
Varma, V.,
and Perry, M. B.
(1996)
Carbohydr. Res.
290,
43-58[CrossRef][Medline]
[Order article via Infotrieve]
-
Szu, S. C.,
Gupta, R.,
and Robbins, J. B.
(1994)
in
Induction of Serum Vibriocidal Antibodies by O-specific Polysaccharide-Protein Conjugate Vaccines for Prevention of Cholera: Vibrio cholerae and Cholera (Wachsmuth, I. K., Blake, P. A., and Olsvik, O., eds), pp. 381-394, American Society for Microbiology, Washington, D. C.
-
Hitsatsune, K.,
Hayashi, M.,
Haishima, Y.,
and Kondo, S.
(1989)
J. Gen. Microbiol.
135,
1901-1907[Medline]
[Order article via Infotrieve]
-
Park, J. T.,
and Johnson, M.
(1949)
J. Biol. Chem.
181,
149-151[Free Full Text]
-
Ková
, P.,
and Lerner, L.
(1988)
Carbohydr. Res.
184,
87-112[CrossRef][Medline]
[Order article via Infotrieve] -
Gotoh, M.,
and Ková
, P.
(1994)
J. Carbohydr. Res.
13,
1193-1213 -
Gotoh, M.,
and Ková
, P.
(1995)
Carbohydr. Res.
268,
73-84[CrossRef][Medline]
[Order article via Infotrieve] -
Lei, P.-S.,
Ogawa, Y.,
Filppen-Anderson, L.,
and Ková
, P.
(1995)
Carbohydr. Res.
275,
117-129[CrossRef][Medline]
[Order article via Infotrieve] -
Lei, P.-S.,
Ogawa, Y.,
and Ková
, P.
(1995)
Carbohydr. Res.
281,
47-60 -
Ogawa, Y.,
Lei, P.-S.,
and Ková
, P.
(1995)
Carbohydr. Res.
277,
327-331[CrossRef][Medline]
[Order article via Infotrieve] -
Zhang, J., and Ková
, P. (1997) J. Carbohydr.
Chem., in press -
Zhang, J.,
and Ková
, P.
(1997)
Carbohydr. Res.
300,
329-339[CrossRef][Medline]
[Order article via Infotrieve] -
Miller, C. E.,
Karpas, A.,
Schneerson, R.,
Huppi, K.,
Ková
, P.,
Poszgay, V.,
and Glaudemans, C. P. J.
(1996)
Mol. Immunol.
33,
1217-1222[CrossRef][Medline]
[Order article via Infotrieve] -
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[CrossRef][Medline]
[Order article via Infotrieve]
-
Kang, A. S.,
Burton, D. R.,
and Lerner, R. A.
(1991)
Methods Companion Methods Enzymol.
2,
111-118
-
Persson, M. A.,
Caothien, R. H.,
and Burton, D. R.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2432-2436[Abstract]
-
Jolley, M. E.,
and Glaudemans, C. P. J.
(1974)
Carbohydr. Res.
33,
377-382[CrossRef][Medline]
[Order article via Infotrieve]
-
Glaudemans, C. P. J.,
Miller, C. E.,
Nashed, E. M.
(1997)
Carbohydr. Res.
300,
169-170[CrossRef][Medline]
[Order article via Infotrieve]
-
Fattom, A.,
Schneerson, R.,
Szu, S. C.,
Vann, W. F.,
Shiloach, J.,
Karakawa, W. W.,
Robbins, J. B.
(1990)
Infect. Immun.
58,
2367-2374[Medline]
[Order article via Infotrieve]
-
Stein, K. E.,
Zopf, D. A. B.,
Johnson, M.,
Miller, C. B.,
Paul, W. E.
(1982)
J. Immunol.
128,
1283-1350
-
Glaudemans, C. P. J.
(1991)
Chem. Rev.
91,
25-33
-
Glaudemans, C. P. J.,
Manjula, B. N.,
Bennett, L. G.,
Bishop, C. T.
(1977)
Immunochemistry
14,
675-679
-
Preston, L. M.,
Xu, Q.,
Johnson, J. A.,
Joseph, A.,
Maneval, D. R., Jr.,
Husain, K.,
Reddy, G. P.,
Bush, C. A.,
Morris, J. G.
(1995)
J. Bacteriol.
177,
835-838[Abstract]
-
Knirel, Y. A.,
Parades, L.,
Jansson, P.-E.,
Weintraub, A.,
Widmalm, G.,
and Albert, M. J.
(1995)
Eur. J. Biochem.
232,
391-396[Abstract]
-
Vinogradov, E. V.,
Bock, K.,
Holst, O.,
and Brade, H.
(1995)
Eur. J. Biochem.
233,
152-158[Abstract]
-
Stroeher, U. H.,
Jedani, K. E.,
Dredge, B. K.,
Morona, R.,
Brown, M. H.,
Karageorgos, L. E.,
Albert, M. J.,
Manning, P. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10374-10378[Abstract]
-
Cox, A. D.,
and Perry, M. B.
(1996)
Carbohydr. Res.
290,
59-65[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.